Biologic Therapy for Osteoarthritis in Stamford, CT

What I’d check before adding osteoarthritis biologic therapy here

Joe Bradley will tell you the same thing he tells his own staff: epidemiology first, then MAC, then SKU. CDC PLACES (2023, crude) estimates 8.6% of adults in Stamford have diagnosed diabetes — 3.4 points below the U.S. 12% figure. 12.3% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. Then we pick osteoarthritis biologic therapy against that mix.

Where Stamford programs actually stall

• Adult arthritis here is 19.3% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 12.3% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Connecticut.
• Skin-substitute and CTP coverage has been rewritten multiple times at the MAC level. Connecticut practices billing National Government Services (NGS) need current LCD/article IDs on the claim, not a distributor slogan about “advanced wound care.”
• Connecticut is outside CDC's historical Diabetes Belt core, but the national 12% diabetes figure still applies as a planning baseline until a clinic uses its own payer mix. Clinics asking for regenerative inventory still have to separate HCT/P 361 homologous-use products from unapproved “stem cell” claims (FDA 21 CFR 1271).

Payer geography for Stamford, CT

JK reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Stamford is 8.6% or not. PLACES is planning data. The LCD is the claim.

How we’d stand this up in clinic